Retatrutide vs Tirzepatide vs Semaglutide: Which Triple Agonist Delivers Superior Research Results in 2026? The world of metabolic research peptides is evolving rapidly. In particular, researchers in 2026 are intensely comparing three leading incretin-based compounds: Semaglutide (single GLP-1 agonist), Tirzepatide (dual GLP-1/GIP agonist), and Retatrutide (triple GLP-1/GIP/glucagon agonist). So, which one shows the most promising […]